1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,040 | 9,300 | 09:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | enVVeno Medical wins FDA IDE for non-surgical transcatheter replacement venous valve | 1 | MassDevice | ||
| Fr | enVVeno Medical erhält FDA-Zulassung für zulassungsrelevante Studie | 2 | Investing.com Deutsch | ||
| Fr | enVVeno Medical GAAP EPS of -$5.37 misses by $2.10 | 2 | Seeking Alpha | ||
| Fr | enVVeno Medical Corporation: enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve | 297 | ACCESS Newswire | Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway... ► Artikel lesen | |
| ENVVENO MEDICAL Aktie jetzt für 0€ handeln | |||||
| Do | enVVeno Medical Corp - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 15.07. | enVVeno Medical Corporation: enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment | 358 | ACCESS Newswire | CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe to Own a Multi-Billion-Dollar Venous Disease MarketWatch the "What This Means" video here IRVINE... ► Artikel lesen | |
| 14.07. | enVVeno Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 07.07. | enVVeno Medical receives U.S. patent for venous valve system | 2 | Investing.com | ||
| 07.07. | enVVeno Medical Corporation: enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial | 699 | ACCESS Newswire | New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billion-Dollar... ► Artikel lesen | |
| 22.06. | enVVeno Medical Corporation: enVVeno Medical to Present in the Webull Corporate Connect Webinar Series | 284 | ACCESS Newswire | - Live webcast on Wednesday, June 24th at 2:00 PM ET- Access the event here IRVINE, CA / ACCESS Newswire / June 22, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"),a company... ► Artikel lesen | |
| 02.06. | enVVeno Medical Corporation: enVVeno Medical to Participate in the Virtual Investor Closing Bell Series | 250 | ACCESS Newswire | Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ETRegister here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation... ► Artikel lesen | |
| 12.05. | enVVeno Medical Corporation: enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment | 445 | ACCESS Newswire | First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous ValveIDE approval positions enVVeno to advance what could become the first effective treatment option for the... ► Artikel lesen | |
| 07.05. | enVVeno Medical GAAP EPS of -$5.89 | 3 | Seeking Alpha | ||
| 07.05. | enVVeno Medical Corporation: enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System | 662 | ACCESS Newswire | Company ended the first quarter with approximately $25 million in cash and investmentsCapital on hand should fund operations through multiple key milestones into Q3 2027Company recently received FDA... ► Artikel lesen | |
| 06.05. | enVVeno Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 29.04. | enVVeno receives FDA approval for venous valve pivotal trial | 2 | Investing.com | ||
| 29.04. | enVVeno Medical Corporation: enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve | 935 | ACCESS Newswire | First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal TrialClinical site activation and patient enrollment expected to commence later this yearLarge unmet clinical need for approximately... ► Artikel lesen | |
| 29.04. | enVVeno Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | enVVeno Medical GAAP EPS of -$33.06 | 2 | Seeking Alpha | ||
| 27.03. | enVVeno Medical Corporation: enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe System | 833 | ACCESS Newswire | Company accelerated development of the enVVe System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiationStrong financial position expected to provide an operating... ► Artikel lesen |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 44,450 | +0,36 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 36,860 | -0,91 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 30,500 | +0,26 % | EQS-AFR: Carl Zeiss Meditec AG: Vorabbekanntmachung über die Veröffentlichung von Quartalsberichten und Quartals-/Zwischenmitteilungen | EQS Vorabbekanntmachung Finanzberichte: Carl Zeiss Meditec AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Carl Zeiss Meditec AG: Vorabbekanntmachung... ► Artikel lesen | |
| ECKERT & ZIEGLER | 13,610 | -1,73 % | Turnaround-Aktien mit fast 200 % Kurspotenzial! Renk, Eckert & Ziegler, Power Metallic Mines! | Rund 50 % hat die Renk-Aktie seit Oktober 2025 verloren. Ist jetzt die Chance zum Einstieg gekommen? Jefferies sieht den fairen Wert immerhin bei 60 EUR. Die kommenden Halbjahreszahlen sollten überzeugen... ► Artikel lesen | |
| INTUITIVE SURGICAL | 306,80 | +0,11 % | Intuitive Surgical: Was UBS jetzt für die Aktie sieht | ||
| GERRESHEIMER | 27,540 | -1,01 % | UBS stuft GERRESHEIMER AG auf 'Sell' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Gerresheimer auf "Sell" mit einem Kursziel von 12,90 Euro belassen. Olivier Calvet passte in einer am Montag vorliegenden... ► Artikel lesen | |
| MEDTRONIC | 74,36 | +0,38 % | Intuitive Surgical (ISRG) vs. Medtronic (MDT): Which MedTech Stock Looks Better Positioned for Growth? | ||
| THERMO FISHER | 500,00 | +0,40 % | Analysts Appear Bullish on Thermo Fisher (TMO): Is The Stock Really a Buy After Earnings? | ||
| TELADOC HEALTH | 5,814 | 0,00 % | Teladoc (TDOC) Stock Plummets on Disappointing Q2 Earnings Results | ||
| STRATEC | 19,520 | -2,01 % | STRATEC: Buy gegen Hold - was der Markt übersieht | ||
| RHOEN-KLINIKUM | 12,900 | 0,00 % | Delegation aus der Ukraine besucht RHÖN-KLINIKUM Campus Bad Neustadt / Fokus auf Telemedizin | Bad Neustadt a. d. Saale (ots) - Campus Bad Neustadt als ausgewählte Station des internationalen Programms "Bayern - Fit for Partnership"Eine 20-köpfige Delegation aus Fach- und Führungskräften sowie... ► Artikel lesen | |
| EUROFINS SCIENTIFIC | 67,98 | -0,41 % | Eurofins Scientific: Director/PDMR Shareholding | Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 59,71 | 0,00 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| FRESENIUS | 44,520 | -0,80 % | Aktien Frankfurt: 'Old economy' schiebt Dax weiter in Richtung Rekordhoch | FRANKFURT (dpa-AFX) - Die weiter nachgebenden Energiepreise haben am deutschen Aktienmarkt am Dienstag für weitere Entspannung gesorgt. Der Dax knüpfte gegen Mittag mit plus 0,61 Prozent auf 25.517... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 14,855 | +0,03 % | Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics | Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 membersRaises the midpoint of all... ► Artikel lesen |
Das Unternehmen ENVVENO MEDICAL CORPORATION kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 9,170 Euro und damit -100,00 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENVVENO MEDICAL CORPORATION finden Sie auf Wallstreet Online.